Drug Safety Experts assess and ensure the safety of pharmaceutical products throughout their lifecycle, from development to post-market surveillance. They focus on identifying, evaluating, and mitigating the risks associated with drug use, including adverse reactions, drug interactions, and long-term effects. These experts play a key role in monitoring the safety of medications once they reach the market, conducting pharmacovigilance to detect and analyze any potential safety concerns that arise in the general population. Their work is essential in protecting public health by ensuring that the benefits of a drug outweigh its risks. They also provide crucial feedback to pharmaceutical companies, ensuring that any potential risks are addressed before the product is launched. These are collaborate with regulatory agencies, pharmaceutical companies, and healthcare providers to ensure that appropriate risk management strategies are in place. They are responsible for analyzing clinical trial data, conducting risk-benefit assessments, and providing recommendations for label changes, warnings, or even drug withdrawals if necessary. Drug safety experts also play a key role in the development of safer drugs, contributing to the design of clinical trials that minimize risks and maximize patient safety. By utilizing sophisticated monitoring techniques and real-time data, they ensure that drugs remain safe for use across diverse populations and over extended periods.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico